Cigna will cover a prostate cancer test developed by MDxHealth, a Belgian company with headquarters in Irvine, Calif.
The Bloomfield, Conn.-based health insurer decided to cover ConfirmMDx for Prostate Cancer after the test was included in the U.S. 2016 National Comprehensive Cancer Network Guidelines for prostate cancer screening.
The test is the first epigenetic and only tissue-based test in the NCCN guidelines that addresses false negative biopsy concerns. It can help urologists identify low-risk men who do not have to be retested, as well as high-risk men who could benefit from intervention, according to a release.
Nearly 2,800 urologists have ordered ConfrimMDx for more than 45,000 patients. The test has also qualified for Medicare, Medicare Advantage and several private health plans.
More articles about payer issues:
Maine health insurance co-op sues feds over $23M of missing ACA payments
Receivership order issued against failed Arizona health insurance co-op
3 Important statistics about provider referrals